Timberlyne Therapeutics

Privately held: no public share price

Assets

(1 total)
1Total Assets
0Approved
1Phase 3 / Filed
0Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Phase 3
CD38Monoclonal antibody
Multiple Myeloma

Upcoming events

(4 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (3)
March 2027 (1)
LumrotatugPhase 2IgA Nephropathy
Est. primary completion 2027-03 · NCT06830395 · CT.gov ↗
What to watch
November 2027 (1)
LumrotatugPhase 1/2Platelet Transfusion Refractoriness
Est. primary completion 2027-11-16 · NCT06792019 · CT.gov ↗
What to watch
December 2027 (1)
LumrotatugPhase 1/2Aplastic Anemia
Est. primary completion 2027-12 · NCT06791824 · CT.gov ↗
What to watch
2030 (1)
May 2030 (1)
LumrotatugPhase 3Multiple Myeloma (MM)
Est. primary completion 2030-05 · NCT07910903 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

No financial reports recorded.